Valneva SE
VALNHealthcare|Biotechnology|FR
$5.51
-0.13 (-2.30%)
Tangible Book / Share
$0.63
Cash / Share
$1.28
Clinical Trials (51)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06928753 Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana | Chikungunya Virus Infection | P4 | Recruiting | 1,505 | Open-label | IXCHIQ, VIMKUNYA |
| NCT04838444 Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) | Chikungunya Virus Infection | P3 | Active | 363 | Open-label | VLA1553 |
| NCT07163845 Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil | Chikungunya Virus Infection | Active | 5,354 | — | Live-attenuated CHIKV vaccine VLA1553 | |
| NCT07254702 Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil | Chikungunya Virus Infection | Active | 5,000 | — | Live-attenuated CHIKV vaccine VLA1553 | |
| NCT01158599 This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population | Japanese Encephalitis | P4 | Completed | 200 | Open-label | IXIARO® |
| NCT03971058 Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals. | Japanese Encephalitis Vaccine | P4 | Unknown | 64 | Open-label | IXIARO®- Japanese Encephalitis vaccine |
| NCT04786444 Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults | Chikungunya Virus Infection | P3 | Completed | 409 | RCT, Double-blind | Biological Vaccine VLA1553 |
| NCT01296360 Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country | Japanese Encephalitis | P3 | Completed | 300 | RCT, Open-label | IXIARO, IXIARO |
| NCT01246479 Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study | Japanese Encephalitis | P3 | Completed | 23 | Open-label | IC51 has given in the parent study IC51-322 |
| NCT05298644 COVID-19 Paediatric VLA2001-321 Study | SARS-CoV-2 Infection | P2P3 | Withdrawn | — | RCT, Double-blind | VLA2001, Active Comparator |
| NCT01563263 Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 | Pseudomonas Aeruginosa Infection | P2P3 | Completed | 803 | RCT, Double-blind | IC43, Placebo |
| NCT01041573 Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population | Encephalitis | P3 | Completed | 1,869 | RCT, Open-label | IC51 Japanese Encephalitis, Havrix®720, Prevnar |
| NCT00595790 Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 | Japanese Encephalitis | P3 | Completed | 374 | RCT, Single-blind | IC51 |
| NCT00595270 Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 | Japanese Encephalitis | P3 | Completed | 349 | Open-label | IC51 |
| NCT04864561 COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 | SARS-CoV-2 Virus Infection | P3 | Completed | 4,034 | RCT, Double-blind | VLA2001, AZD1222, VLA2001 - adolescent part, Placebo |
| NCT04650399 A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents | Chikungunya | P3 | Completed | 754 | RCT, Double-blind | Active, Placebo |
| NCT07133178 A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children | Chikungunya Virus Infection | P3 | Withdrawn | — | RCT, Double-blind | VLA1553, Control |
| NCT00594958 Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 | Japanese Encephalitis | P3 | Completed | 639 | RCT, Double-blind | IC51 |
| NCT05477524 An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) | Lyme Disease | P3 | Completed | 12,546 | RCT, Double-blind | VLA15 |
| NCT00604708 Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 | Japanese Encephalitis | P3 | Completed | 867 | RCT, Single-blind | IC51, JE-VAX |
| NCT04546724 Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults | Chikungunya Virus Infection | P3 | Completed | 4,128 | RCT, Double-blind | VLA1553, Placebo |
| NCT01047839 Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries | Encephalitis | P3 | Completed | 100 | Open-label | IC51, IC51, IC51 |
| NCT05364242 VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection | SARS-CoV-2 Infection | P2P3 | Completed | 178 | Open-label | VLA2001 |
| NCT00605085 Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 | Japanese Encephalitis | P3 | Completed | 2,675 | RCT, Double-blind | Japanese Encephalitis purified inactivated vaccine (IC51), Placebo |
| NCT04956224 Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years | SARS-CoV-2 Virus Infection | P3 | Completed | 306 | Open-label | VLA2001 |
| NCT00595465 Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 | Japanese Encephalitis | P3 | Completed | 389 | RCT, Double-blind | Japanese Encephalitis purified inactivated vaccine |
| NCT06028841 A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) | Chikungunya Virus Infection | P3 | Withdrawn | — | Open-label | VLA1553 |
| NCT00595309 Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 | Japanese Encephalitis | P3 | Completed | 198 | Open-label | IC51 |
| NCT00776230 Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling | Japanese Encephalitis | P3 | Completed | 304 | Open-label | IC51 |
| NCT00596271 Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 | Japanese Encephalitis | P3 | Completed | 192 | RCT, Single-blind | IC51, HAVRIX |
| NCT06106581 A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years | Chikungunya Virus Infection | P2 | Completed | 304 | RCT, Double-blind | VLA1553 full dose, VLA1553 half dose, Control |
| NCT00601770 Virological Response Study of the HCV Vaccine IC41 | Chronic Hepatitis C | P2 | Completed | 71 | Open-label | IC41 |
| NCT00876252 Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients | Pneumonia, Ventilator-Associated | P2 | Completed | 400 | RCT, Double-blind | IC43, Placebo |
| NCT03970733 Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis | Lyme Borreliosis | P2 | Completed | 246 | RCT, Double-blind | VLA15, Placebo |
| NCT03576183 Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701 | Enterotoxigenic Escherichia Coli Infection, Diarrhea | P2 | Completed | 34 | RCT, Double-blind | VLA1701, Placebo |
| NCT04671017 Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects | SARS-CoV-2 Virus Infection | P1P2 | Completed | 153 | RCT, Double-blind | VLA2001 |
| NCT02316470 Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study | Clostridium Difficile | P2 | Completed | 500 | RCT, Double-blind | VLA84, Placebo |
| NCT04801420 Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population | Lyme Borreliosis | P2 | Completed | 625 | RCT, Double-blind | VLA15, Placebo |
| NCT00602784 Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine | Chronic Hepatitis C | P2 | Completed | 66 | RCT, Double-blind | IC41 |
| NCT00778388 Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers | Healthy | P1 | Completed | 157 | RCT, Double-blind | IC43, Placebo |
| NCT03382964 Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers | Chikungunya | P1 | Completed | 120 | RCT, Double-blind | VLA1553 |
| NCT03010228 Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis | Lyme Borreliosis, Nervous System | P1 | Completed | 179 | RCT, Double-blind | VLA15 with Alum, VLA15 without Alum |
| NCT03425149 Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults | Zika Virus, Zika Virus Infection | P1 | Completed | 67 | RCT, Double-blind | VLA1601, Placebo |
| NCT01559831 Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination | Japanese Encephalitis | P1 | Withdrawn | — | Open-label | IXIARO |
| NCT01296386 An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 | Clostridium Difficile Infection | P1 | Completed | 82 | RCT, Open-label | IC84 |
| NCT00873431 Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47 | Pneumococcal Infections | P1 | Completed | 32 | RCT, Open-label | IC47 |
| NCT06334393 Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults | Zika, Zika Virus Infection | P1 | Completed | 150 | RCT, Double-blind | VLA1601, CpG 1018®, 3M-052-AF |
| NCT07414524 VLA1553-403 Pregnancy Surveillance Study | Chikungunya Virus Infection | By Invite | 200 | — | Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH | |
| NCT01335412 Safety Surveillance After Immunization With IXIARO | Japanese Encephalitis | Completed | 20,000 | — | Japanese Encephalitis Virus vaccine, inactivated, adsorbed | |
| NCT00596102 Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 | Japanese Encephalitis | Completed | 3,258 | — | Japanese Encephalitis purified inactivated vaccine | |
| NCT07347002 Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil | Chikungunya Virus Infection | By Invite | 1,200 | — | Live-attenuated CHIKV vaccine VLA1553 |